Page 20 - மருந்து நிறுவனம் வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share: EAGAN, Minn., Dec. 16, 2020 /PRNewswire/  In an effort to help assess the value of hemophilia A treatments relative to total health care costs and emergency department visits, Prime Therapeutics LLC (Prime) has finalized an arrangement with Takeda Pharmaceuticals America, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (NYSE:TAK) ( Takeda ) for the factor replacement product ADVATE ® [Antihemophilic Factor (Recombinant)], which is used in the treatment and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency). Hemophilia treatment options have increased in recent years, including innovative therapies. However, these innovations come at a high price. Therefore, it is important to establish integrated medical and pharmacy benefit contracts between payers and product manufacturers on existing treatments. The arrangement between Prime and Takeda provides:

United statesRichard ascroftKelly mcgrailBetter healthFast facts national hemophilia foundationTakeda pharmaceutical company limitedTakeda pharmaceutical companyHemophilia national foundationTakeda pharmaceuticals america incNational hemophilia foundationPrime therapeuticsTakeda pharmaceuticals americaKelly mcgrail pokutaHemophilia foundationAsked questions about hemophiliaBlue shield plans